{"Title":"Quanterix","Industry":"LABORATORY ANALYTICAL INSTRUMENTS","Employees":"122","Founded":"","Address":"","Phone":"(617) 301-9400","Web_address":"http://www.quanterix.com","Market_cup":"$317.85mil","Revenues":"$23.0 mil (last 12 months)","Net_income":"$-31.4 mil (last 12 months)","Symbol":"QTRX","Exchange":"NASDAQ","Shares":"4.3","Price_range":"$15.00 - $15.00","Est_volume":"$64.1 mil","Manager":"J.P. Morgan/ Leerink Partners","CO_managers":"BTIG/ Evercore ISI","Exp_to_trade":"12/7/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Our platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies."}